Pharmacological interventions that increase myofiber size counter the functional decline of dystrophic muscles. We show that deacetylase inhibitors increase the size of myofibers in dystrophin-deficient (MDX) and α-sarcoglycan (α-SG)-deficient mice by inducing the expression of the myostatin antagonist follistatin in satellite cells. Deacetylase inhibitor treatment conferred on dystrophic muscles resistance to contraction-coupled degeneration and alleviated both morphological and functional consequences of the primary genetic defect. These results provide a rationale for using deacetylase inhibitors in the pharmacological therapy of muscular dystrophies.
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors / G.C. Minetti,C. Colussi, R. Adami, C. Serra, C. Mozzetta, V. Parente, S. Fortuni, S. Straino, M. Sampaolesi, M. Di Padova, B. Illi, P. Gallinari, C. Steinkühler, M.C. Capogrossi, V. Sartorelli, R. Bottinelli, C. Gaetano, P. L. Puri. - In: NATURE MEDICINE. - ISSN 1078-8956. - 12:10(2006 Sep 17), pp. 1147-1150. [10.1038/nm1479]
Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors
R. Adami;
2006
Abstract
Pharmacological interventions that increase myofiber size counter the functional decline of dystrophic muscles. We show that deacetylase inhibitors increase the size of myofibers in dystrophin-deficient (MDX) and α-sarcoglycan (α-SG)-deficient mice by inducing the expression of the myostatin antagonist follistatin in satellite cells. Deacetylase inhibitor treatment conferred on dystrophic muscles resistance to contraction-coupled degeneration and alleviated both morphological and functional consequences of the primary genetic defect. These results provide a rationale for using deacetylase inhibitors in the pharmacological therapy of muscular dystrophies.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.